Ultime notizie per Exelixis (NASDAQ:EXEL) Azioni

EXELIXIS INC

Exelixis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Exelixis will report an earnings per share (EPS) of $0.61.
The market awaits Exelixis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.18 in the last quarter, leading to a 20.84% increase in the share price on the following day.
Here's a look at Exelixis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.49</td>
<td>0.35</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.62</td>
<td>0.55</td>
<td>0.47</td>
<td>0.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>21.0%</td>
<td>-0.0%</td>
<td>13.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455687_0.png" alt="eps graph" />
<h3>Market Performance of Exelixis's Stock</h3>
Shares of Exelixis were trading at $44.79 as of July 24. Over the last 52-week period, shares are up 94.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Exelixis</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis.
The consensus rating for Exelixis is Buy, based on 14 analyst ratings. With an average one-year price target of $48.5, there's a potential 8.28% upside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Neurocrine Biosciences, Moderna and BioMarin Pharmaceutical, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Neurocrine Biosciences, with an average 1-year price target of $154.0, suggesting a potential 243.83% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Moderna, with an average 1-year price target of $36.83, suggesting a potential 17.77% downside.</li>
<li>Analysts currently favor an Outperform trajectory for BioMarin Pharmaceutical, with an average 1-year price target of $97.75, suggesting a potential 118.24% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Neurocrine Biosciences, Moderna and BioMarin Pharmaceutical, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>30.62%</td>
<td>$536.27M</td>
<td>7.30%</td>
</tr>
<tr>
<td>Neurocrine Biosciences</td>
<td>Buy</td>
<td>11.12%</td>
<td>$563.40M</td>
<td>0.31%</td>
</tr>
<tr>
<td>Moderna</td>
<td>Neutral</td>
<td>-35.93%</td>
<td>$17M</td>
<td>-9.26%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>Outperform</td>
<td>14.84%</td>
<td>$593.59M</td>
<td>3.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Exelixis ranks highest in revenue growth and gross profit among its peers. However, it has the lowest return on equity. Overall, Exelixis is positioned favorably compared to its peers in terms of financial performance.
<h3>Unveiling the Story Behind Exelixis</h3>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Exelixis's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 30.62%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's net margin excels beyond industry benchmarks, reaching 28.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.3% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.52%, the company showcases effective utilization of assets.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/EXEL/earnings">To track all earnings releases for Exelixis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

EXEL

Uncovering Potential: Exelixis's Earnings Preview

– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –
– CABOMETYX is the first and only systemic therapy to be approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exelixis.com%2F&amp;esheet=54296414&amp;newsitemid=20250724850513&amp;lan=en-US&amp;anchor=Exelixis%2C+Inc.&amp;index=1&amp;md5=e8f7628f70d3d2f87fd276766415d0d6">Exelixis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX&#xAE; (cabozantinib) for the treatment of adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.exelixis.com%2Fnews-releases%2Fnews-release-details%2Fexelixis-partner-ipsen-receives-positive-chmp-opinion-1&amp;esheet=54296414&amp;newsitemid=20250724850513&amp;lan=en-US&amp;anchor=positive+opinion&amp;index=2&amp;md5=3c21cff5aa706ddbcc6cc5c65ddaa869">positive opinion</a> received from the European Medicines Agency's Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland.

Biotech

News

Global

General

Exelixis Announces EU Approval Of CABOMETYX As First Systemic Therapy For Previously Treated Neuroendocrine Tumors

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has fallen 4.97% since its last report. The company recently reported that it has 19.38 million shares sold short, which is 9.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753189234_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 6.34%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Exelixis's Recent Short Interest

Morgan Stanley analyst Jefferson Harralson maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $47 to $48.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $48

Truist Securities analyst Asthika Goonewardene maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $55 to $56.

Truist Securities Maintains Buy on Exelixis, Raises Price Target to $56

In the last three months, 12 analysts have published ratings on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $47.75, with a high estimate of $60.00 and a low estimate of $38.00. Observing a 18.87% increase, the current average has risen from the previous average price target of $40.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1752181216_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exelixis's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>Get to Know Exelixis Better</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, Exelixis showcased positive performance, achieving a revenue growth rate of 30.62% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's net margin excels beyond industry benchmarks, reaching 28.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 7.3%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.52% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Exelixis: Insights From 12 Financial Analysts

Barclays analyst Peter Lawson maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Equal-Weight and raises the price target from $29 to $40.

Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $40

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has risen 9.62% since its last report. The company recently reported that it has 20.39 million shares sold short, which is 10.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751648419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 6.26%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HC Wainwright &amp; Co. analyst Robert Burns maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $47 to $53.

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $53

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Macquarie analyst Aditya Suresh upgraded the rating for MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) from Neutral to Outperform and announced a $110 price target. MakeMyTrip shares closed at $91.51 on Monday. <a href="https://www.benzinga.com/quote/mmyt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst DS Kim upgraded New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Neutral to Overweight and raised the price target from $48 to $62. New Oriental Education shares closed at $49.05 on Tuesday. <a href="https://www.benzinga.com/quote/edu/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Sudan Loganathan upgraded Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Equal-Weight to Overweight and raised the price target from $29 to $60. Exelixis shares closed at $43.37 on Tuesday. <a href="https://www.benzinga.com/quote/exel/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MMYT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/MMYT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24083222/image-359-1024x581.png" alt="" class="wp-image-959797" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24083222/image-359-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24083222/image-359-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24083222/image-359-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24083222/image-359.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Upgrades

Markets

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

CRDF

New Oriental Education & Technology Group

GLXY

MMYT

This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday

Stephens &amp; Co. analyst Sudan Loganathan upgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Equal-Weight to Overweight and raises the price target from $29 to $60.

Stephens & Co. Upgrades Exelixis to Overweight, Raises Price Target to $60

Truist Securities analyst Asthika Goonewardene reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $43 to $55.

Reiteration

Truist Securities Reiterates Buy on Exelixis, Raises Price Target to $55

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply during Monday's session amid the Robotaxi <a href="https://www.benzinga.com/markets/tech/25/06/46051889/teslas-4-20-robotaxi-disruption-waymo-should-be-worried">launch in Austin, TX</a>.
Tesla has officially rolled out its much-awaited Robotaxi in Austin, Texas, with a limited number of Model Y Robotaxis in the South Congress neighborhood.
&#8220;Our approach to autonomy also enables scalability: Tesla self-driving can be deployed anywhere it's approved,&#8221; the company said in a post on social media platform X on Sunday after the Robotaxi launch.
Tesla shares jumped 9.3% to $352.11 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>SpartanNash Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPTN#NASDAQ">SPTN</a>) shares jumped 49.5% to $26.36 after the company announced it will be acquired by C&amp;S Wholesale Grocers.</li>
<li>Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) gained 36.3% to $1.43 after the company announced a strategic sale of SomaLogic to Illumina.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) rose 25.6% to $17.10 after the company raised its second-quarter net sales guidance.</li>
<li>Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) gained 20.2% to $17.05.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) rose 19% to $26.47.</li>
<li>Epsium Enterprise Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) gained 16.5% to $26.62.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) rose 14.8% to $275.90 after the company announced a partnership with Fiserv to use its stablecoin platform with Fiserv&#8217;s digital banking and payment capabilities.</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) gained 13% to $2.9479 after announcing positive six-month clinical results from Type 1 diabetes study of Islet Cell Transplantation without Immunosuppression.</li>
<li>Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) rose 11.8% to $24.11.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) gained 10% to $44.39 after the company topline results from the STELLAR-303 phase 3 pivotal trial. Also, JMP Securities raised its price target on the stock from $47 to $50.</li>
<li>Scholastic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) rose 9.4% to $20.92 as the company issued update on strategic and operational initiatives.</li>
<li>Northern Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) gained 8.5% to $121.44 following a report suggesting the Bank of New York Mellon approached the company to discuss a potential merger.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) gained 8% to $7.83 as the company said Côté Gold Mine reached major milestone as processing plant operated at nameplate capacity of 36,000 tpd on average over thirty consecutive days.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) climbed 5.8% to $18.38.</li>
<li>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) rose 4.7% to $442.01 following upbeat quarterly sales.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

AIRO

CRCL

CRMD

EPSM

MANU

NTRS

OUST

SANA

SCHL

SPTN

TSLA

ZETA

Tesla, SpartanNash, Standard BioTools And Other Big Stocks Moving Higher On Monday

On Sunday, Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46044198/exelixis-announces-zanzalintinib-in-combination-with-an-immune-checkpoint-inhibitor-improved-overa" rel="noreferrer noopener">combined with atezolizumab</a>.
The study includes patients with previously treated non-microsatellite instability (MSI)-high <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">metastatic colorectal cancer (CRC)</a>.
Zanzalintinib in combination with Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) atezolizumab (Tecentriq) demonstrated a statistically significant improvement in overall survival (OS) versus Bayer AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>) Stivarga (regorafenib).
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45418036/exelixis-stock-soars-as-analysts-applaud-raised-2025-guidance-q1-earnings-beat" target="_blank" rel="noreferrer noopener">Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat</a>
These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial.
The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM).
The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified.
Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference.
Following this positive news, analysts at William Blair said that the announcement &#8220;represents the first pivotal success from the zanzalintinib program, and we are encouraged that the STELLAR-303 study met one of the dual primary endpoints of overall survival among the intent-to-treat population, representing the largest commercial opportunity (risk-adjusted U.S. peak sales of $875 million, according to our estimates).&#8221;
Management had earlier projected that zanzalintinib could reach $5 billion in U.S. net product sales by 2033, with 45% expected from genitourinary cancers, another 45% from gastrointestinal cancers, and the remaining 10% from head-and-neck cancers. Analyst Andy Hsieh asserted that the early positive results from the STELLAR-303 trial mark the first step toward reaching that target.
He added, &#8220;From a stock perspective, given its substantial and likely durable cash flow generation into early 2030, we continue to believe Exelixis provides investors with a highly defensive investment profile. We also believe that the strategic positioning outlined by Exelixis should drive moderate growth into the next decade.&#8221;
Adding to Exelixis&#8217; recent positive developments, its partner Ipsen also recently achieved a regulatory milestone.
On Friday, Exelixis&#8217; partner Ipsen received a positive opinion from the European Medicine Agency&#8217;s Committee for Medicinal Products for Human Use for Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic and pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46022267/exelixis-partner-ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-patients-with" rel="noreferrer noopener">other than somatostatin analogs</a>.
A regulatory decision by the European Medicines Agency is anticipated in 2025. In March 2025, the U.S. Food and Drug Administration approved <a href="https://www.benzinga.com/pressreleases/25/06/b46022267/exelixis-partner-ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-patients-with" target="_blank" rel="noreferrer noopener">Cabometyx in this setting</a>.
Price Action: EXEL stock is trading higher by 11.1% to $44.85 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/05/45703024/pfizer-reports-survival-gains-in-colorectal-cancer-study-combo-therapy-cuts-death-risk-by-over-50" target="_blank" rel="noreferrer noopener">Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Health Care

BAYRY

RHHBY

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>B of A Securities lowered Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) price target from $300 to $285. B of A Securities analyst Heather Balsky downgraded the stock from Buy to Neutral. Equifax shares closed at $255.70 on Friday. <a href="https://www.benzinga.com/quote/EFX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities increased the price target for Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from $47 to $50. JMP Securities analyst Silvan Tuerkcan maintained a Market Outperform rating. Exelixis shares closed at $40.37 on Friday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc raised Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) price target from $230 to $245. Keybanc analyst Eric Gonzalez maintained an Overweight rating. Darden shares closed at $225.78 on Friday. <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital slashed the price target for Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from $29 to $22. BMO Capital analyst John McNulty downgraded the stock from Market Perform to Underperform. Dow shares closed at $27.76 on Friday. <a href="https://www.benzinga.com/quote/DOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) from $22 to $25. Baird analyst Rob Oliver downgraded the stock from Outperform to Neutral. Couchbase shares closed at $24.49 on Friday. <a href="https://www.benzinga.com/quote/BASE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) price target from $3 to $8. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. FMC shares settled at $41.07 on Friday. <a href="https://www.benzinga.com/quote/FMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) price target from $73 to $82. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating. Kroger shares closed at $71.97 on Friday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank increased Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) price target from $14 to $22. Deutsche Bank analyst David Begleiter maintained a Buy rating. Compass Minerals shares closed at $19.38 on Friday.  <a href="https://www.benzinga.com/quote/CMP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised the price target for Corteva, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) from $79 to $82. Wells Fargo analyst Richard Garchitorena maintained an Overweight rating. Corteva shares settled at $73.72 on Friday. <a href="https://www.benzinga.com/quote/CTVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Melius Research increased Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) price target from $110 to $175. Melius Research analyst Ben Reitzes upgraded the stock from Hold to Buy. AMD shares closed at $128.24 on Friday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/AMD/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="609" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-1024x609.png" alt="" class="wp-image-958196" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-1024x609.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334-768x457.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/23095218/image-334.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

BASE

CTVA

AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday

Across the recent three months, 9 analysts have shared their insights on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $45.0, a high estimate of $56.00, and a low estimate of $38.00. This upward trend is apparent, with the current average reflecting a 8.28% increase from the previous average price target of $41.56.
<img src="https://www.benzinga.com/files/images/story/2025/1750683642_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Exelixis. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exelixis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Exelixis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Exelixis displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 30.62%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.3%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 5.52%. This signifies efficient management of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 9 Analyst Ratings Have To Say About Exelixis

WIIM

Exelixis shares are trading higher after the company topline results from the STELLAR-303 phase 3 pivotal trial. Also, JMP Securities raised its price target on the stock from $47 to $50.

<h3>Gainers</h3>
<ul>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock increased by 141.3% to $0.65 during Monday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 104.55% to $0.74. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares moved upwards by 66.84% to $35.07. The company's market cap stands at $272.6 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock moved upwards by 40.78% to $20.64. The company's market cap stands at $96.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares moved upwards by 33.18% to $0.59. The market value of their outstanding shares is at $18.4 million. </li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) stock increased by 23.13% to $49.71. The market value of their outstanding shares is at $11.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares declined by 35.2% to $3.0 during Monday's pre-market session. The company's market cap stands at $433.1 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares declined by 21.39% to $5.44. The company's market cap stands at $1.3 billion. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares decreased by 18.19% to $3.51. The market value of their outstanding shares is at $7.0 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 17.13% to $53.22. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.13% to $0.27. The company's market cap stands at $3.8 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 13.32% to $3.06. The market value of their outstanding shares is at $10.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARM

CDTX

CMPS

FBRX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INDP

LUCY

PCSA

SSII

TCRT

12 Health Care Stocks Moving In Monday's Pre-Market Session

JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and raises the price target from $47 to $50.

JMP Securities Maintains Market Outperform on Exelixis, Raises Price Target to $50

Shares of Sequans Communications S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) rose sharply in today's pre-market trading after the company announced a $384 million strategic investment to launch a <a href="https://www.benzinga.com/quote/SQNS">bitcoin treasury initiative</a>.
Sequans Communications shares jumped 42.2% to $2.72 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>OceanPal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) surged 86.1% to $2.68 in pre-market trading after dipping around 35% on Friday.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares jumped 51.3% to $0.4086 in pre-market trading after tumbling 18% on Friday.</li>
<li>DIH Holding US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) gained 47.5% to $0.3260 in pre-market trading.</li>
<li>Houston American Energy Corp.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) gained 30.7% to $19.41 in pre-market trading after dipping 15% on Friday.</li>
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) rose 29.5% to $7.93 in pre-market trading. Robin Energy shares dipped 30% on Friday after the company announced the pricing of a $4.0M offering of 763,000 shares at $5.25 per share.</li>
<li>TMD Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NASDAQ">TMDE</a>) jumped 28.2% to $2.57 in pre-market trading after falling more than 5% on Friday.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) fell 25.2% to $50.56 in pre-market trading after the company disclosed that Zanzalintinib combination with Atezolizumab achieved survival benefit in intent-to-treat population of metastatic colorectal cancer patients.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) climbed 17.6% to $16.67 in pre-market trading after gaining more than 12% on Friday.</li>
<li>W&amp;T Offshore, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) gained 9.1% to $2.36 in pre-market trading after falling 9% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares tumbled 30.8% to $3.20 in pre-market trading. Compass Pathways said it successfully achieved primary endpoint in first Phase 3 trial evaluating COMP360 psilocybin for treatment-resistant depression.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares fell 30.2% to $2.38 in pre-market trading after jumping over 158% on Friday.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) dipped 28.2% to $0.2293 in pre-market trading after falling around 6% on Friday.</li>
<li>SS Innovations International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) declined 20.7% to $5.49 in pre-market trading after gaining around 42% on Friday.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) declined 17.3% to $0.2079 in pre-market trading after gaining 15% on Friday.</li>
<li>Moving iMage Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NASDAQ">MITQ</a>) dipped 17% to $0.7055 in pre-market trading. Moving iMage Technologies shares jumped 54% on Friday after the company announced a $9 million contract with a national cinema exhibition customer regarding the sale and installation of 150 Barco laser projections along with a range of MIT-manufactured equipment..</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) fell 16.8% to $1.09 in pre-market trading after the company announced it received a delisting notice from the Nasdaq.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) fell 16% to $2.21 in pre-market trading after jumping 70% on Friday.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) fell 15.4% to $0.27 in pre-market trading after gaining 32% on Friday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 11.9% to $33.50 in pre-market trading after dipping 40% on Friday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46023851/top-2-tech-stocks-that-could-sink-your-portfolio-in-june">Top 2 Tech Stocks That Could Sink Your Portfolio In June</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

CTOR

DFLI

DHAI

HUSA

MITQ

MRIN

Next Technology Holding Inc. - Ordinary Shares

NXTT

RBNE

SISI

SQNS

TMDE

Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket

Press Releases

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Small Cap

Opinion

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Comments

Exelixis

Notizie

Ultime notizie per Exelixis (NASDAQ:EXEL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO